GoldenGolden
Acorda Therapeutics

Acorda Therapeutics

Acorda is a biotechnology company founded in 1995 by Ron Cohen and headquartered in Ardsley, New York developing and commercializing neurology therapies for Parkinson's disease, migraines, and multiple sclerosis.

Acroda Therapeutics is a biotechnology company based out of Ardsley, New York that was founded in 1995 by Ron Cohen. The company is working to develop and commercialize treatments for neurological disorders of the central nervous system such as multiple sclerosis, spinal cord injuries, and Parkinson's disease.

Acquisitions
Biotie Therapies

On January 19, 2016 Acorda Therapeutics acquired Biotie Therapies for $25.60 per share for a total of approximately $363 million. Acorda Therapeutics bought Biotie Therapies to acquire two of its drug candidates for the treatment of Parkinson's disease called Tozadenant and SYN120.

Timeline

1995
Acorda Therapeutics was founded by Ron Cohen.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Acorda Therapeutics Grant October 1997
2,000,000
4 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Abhijit Kamerkar

Employee

Akshat K Goyal

Employee

Anders Boman

Employee

Andrew Blight

Chief Scientific Officer

Andrew Hindman

Chief Business Officer

Burkhard Blank

Chief Medical Officer

Catherine Carlstedt

Employee

Christian Richardson

Employee

Christian Sabella

Employee

Daniel Aleshinloye

Employee

David Lawrence

Chief Business Operations and Principal accounting Officer

Denise Duca

Executive Vice President

Derk de Groot

Employee

Eric Chojnicki, Ph.D., M.B.A., PMP, CSSBB

Employee

Grant Levy

Employee

jane Wasman

President of International & General Counsel

Jon Mason

Employee

Kyle Kuhn

Employee

Lauren Sabella

Chief Commercial Officer

Mary Lou Nadeau

Employee

Ned McDonnell

Employee

Oksana Hradyska

Employee

Ron Cohen

Founder, President & CEO

Sissi Hai

Employee

Susan Veres

Employee

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

Acorda Therapeutics investor calls for company to explore sale

Greg Roumeliotis

News

What's Behind Acorda Therapeutics Crashing 24.5% Today -- The Motley Fool

Todd Campbell

News

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
November 16, 2020
BioSpace
Addition deepens board expertise to prepare for future growth and potential commercialization of MultiStem®

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.